Skip to content

Myriad beats, ups guidance

May 3, 2017

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.27, $0.04 better than the analyst estimate of $0.23. Revenue for the quarter came in at $196.9 million versus the consensus estimate of $189.1 million.

GUIDANCE:

Myriad Genetics sees Q4 2017 EPS of $0.26-$0.28. Myriad Genetics sees Q4 2017 revenue of $192-194 million.

Myriad Genetics sees FY 2017 EPS of $1.01-$1.03 Myriad Genetics sees FY 2017 revenue of $763-765 million.

http://bit.ly/2qA5WT3

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: